ClinicalTrials.gg
CompletedNCT01509755Updated Jan 24, 2017

Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes

A Phase 2 interventional study of placebo and liraglutide in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 29 sites in 4 countries. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-01-24.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 2 and Interventional

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
196
Ages
30 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 151 studies testing liraglutide in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 1 of them phase 3. Liraglutide · Diabetes Mellitus, Type 2.

Planned enrollment
46th of 151
196 · median 62
Started
2000
the only one that year
Phase 2
18 of 151
2 open now
Registered
37th of 151
by date
Lead sponsor
63 of 151
Novo Nordisk A/S

Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, this one is the 46th largest by planned enrollment, is the only one that started in 2000, is one of 18 in phase 2, and was the 37th registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 151 studies testing liraglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About liraglutide

Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 30 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 151 studies testing liraglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted in Europe. The aim of this trial is to establish the dose response relationship on glycaemic control of five dose levels of NNC90-1170.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

This study's planned enrollment of 196 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
30 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with type 2 diabetes
  • Duration of diabetes at least 3 months
  • Both diet treated and patients in therapy with OHA (oral hypoglycemic agents)
  • maximum 40 kg/m\^2
  • based on analysis from central laboratory: Between 7.5-10.0%, both inclusive, for diet treated, or maximum 9.0% for OHA treated

Exclusion criteria

Exclusion Criteria:

  • Liver or renal disease
  • Cardiac problems
  • Uncontrolled treated/untreated hypertension
  • Proliferative retinopathy
  • Recurrent severe hypoglycaemia as judged by the Investigator
  • Known or suspected allergy to trial product or related products
  • Use of any drug (except for OHAs) which in the Investigator's opinion could interfere with the blood glucose level
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

06

Study design

Phase
Phase 2
Enrollment
196 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Drug: placebo

  • Experimental
    0.045 mg

    Drug: liraglutide

  • Experimental
    0.225 mg

    Drug: liraglutide

  • Experimental
    0.45 mg

    Drug: liraglutide

  • Experimental
    0.60 mg

    Drug: liraglutide

  • Experimental
    0.75 mg

    Drug: liraglutide

  • Active comparator
    Glim

    Drug: placebo · Drug: glimepiride

Interventions

  • Drugplacebo

    Once daily injection, under the skin (s.c.) for 12 weeks

  • Once daily injection, under the skin (s.c.) for 12 weeks

    Also known as: NNC 90-1170

  • Tablets administered orally according to current treatment guidelines. Dose adjusted according to the glycaemic response

07

What researchers measure

Primary outcomes

  1. HbA1c (glycosylated haemoglobin)

Secondary outcomes

  1. Fasting plasma glucose

  2. Fructosamine

  3. 7-point blood glucose profile

  4. Adverse events

08

Study locations

29 sites
  • Novo Nordisk Investigational Site
    Hvidovre, 2650, Denmark
  • Novo Nordisk Investigational Site
    Kolding, 6000, Denmark
  • Novo Nordisk Investigational Site
    København, 2400, Denmark
  • Novo Nordisk Investigational Site
    Køge, 4600, Denmark
  • Novo Nordisk Investigational Site
    Thisted, 7700, Denmark
  • Novo Nordisk Investigational Site
    Århus C, 8000, Denmark
  • Novo Nordisk Investigational Site
    Bekkestua, 1357, Norway
  • Novo Nordisk Investigational Site
    Elverum, 2408, Norway
  • Novo Nordisk Investigational Site
    Harstad, 9480, Norway
  • Novo Nordisk Investigational Site
    Oslo, 0370, Norway
  • Novo Nordisk Investigational Site
    Grästorp, 467 22, Sweden
  • Novo Nordisk Investigational Site
    Göteborg, 413 45, Sweden
  • Novo Nordisk Investigational Site
    Lund, 221 85, Sweden
  • Novo Nordisk Investigational Site
    Uppsala, 751 85, Sweden
  • Novo Nordisk Investigational Site
    Örebro, 701 85, Sweden
  • Novo Nordisk Investigational Site
    Ayrsh, KA2 0BE, United Kingdom
  • Novo Nordisk Investigational Site
    Church Village, CF38 1AB, United Kingdom
  • Novo Nordisk Investigational Site
    Edinburgh, EH16 4SA, United Kingdom
  • Novo Nordisk Investigational Site
    Enfield, EN2 8JL, United Kingdom
  • Novo Nordisk Investigational Site
    Hull, HU3 2JZ, United Kingdom
  • Novo Nordisk Investigational Site
    Leicester, LE5 4PW, United Kingdom
  • Novo Nordisk Investigational Site
    Liverpool, L7 8XP, United Kingdom
  • Novo Nordisk Investigational Site
    Northampton, NN1 5BD, United Kingdom
  • Novo Nordisk Investigational Site
    Nottingham, NG7 2UH, United Kingdom
  • Novo Nordisk Investigational Site
    Oxford, OX2 6HE, United Kingdom
  • Novo Nordisk Investigational Site
    Plymouth, PL8 8DQ, United Kingdom
  • Novo Nordisk Investigational Site
    Rugby, CV22 5PX, United Kingdom
  • Novo Nordisk Investigational Site
    Sheffield, S5 7AU, United Kingdom
  • Novo Nordisk Investigational Site
    Worksop, S81 OBD, United Kingdom
09

References and documents

Publications

  • Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR; NN2211-1310 International Study Group. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care. 2004 Jun;27(6):1335-42. doi: 10.2337/diacare.27.6.1335. PubMed 15161785 ↗
  • Jensen TM, Saha K, Steinberg WM. Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care. 2015 Jun;38(6):1058-66. doi: 10.2337/dc13-1210. Epub 2014 Dec 12. Erratum In: Diabetes Care. 2015 Aug;38(8):1622. doi: 10.2337/dc15-er08. PubMed 25504028 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2000, a primary completion of Oct 2001 and a completion of Oct 2001. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2012
First posted
Jan 13, 2012
Start
Oct 2000
Primary completionActual
Oct 2001
CompletionActual
Oct 2001
Last update
Jan 24, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01509755
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jan 13, 2012
Start date
Oct 2000
Primary completion
Oct 2001
Completion
Oct 2001
Last update
Jan 24, 2017

Study contacts

Global Clinical Registry (GCR, 1452), MD
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liraglutide

Start the discussion